Skip to main content
. 2018 Dec 11;9:2824. doi: 10.3389/fimmu.2018.02824

Figure 1.

Figure 1

ISG induction by SLE serum requires either RAGE or FcRlla. (A) Primary human monocytes were incubated with serum from different SLE patients, B2, M91, B31, F72, or control sera, for 4 h. ISG expression was evaluated using qPCR. Data plotted represents fold induction for each gene relative to the sample incubated with control serum and is representative of 30 samples tested. (B) RAGE and FcRlla levels in monocytes treated with RAGE or FcRIIa siRNA, assessed by qPCR. (C) Monocytes were transfected with RAGE, FcRlla, or control siRNA, prior to incubation with SLE serum for 4 h. For each sample (control, RAGE, or FcRlla siRNA transfected cells) fold induction of ISGs was calculated as the ratio of gene expression between treated and untreated cells. (D) Primary human monocytes were treated with SLE serum, with or without sRAGE or monoclonal anti-FcRlla antibody for 4 h. ISG expression was analyzed by qPCR. Results in each case (B–D) indicate mean ± SD of three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001.